FrancophonIA/ELRC3.0 huggingface dataset:
English: In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with Enviage 300 mg provided additional blood pressure reduction that was comparable to add-on treatment with irbesartan 300 mg or amlodipine 10 mg.
Slovenian: Pri debelih bolnikih s hipertenzijo, ki se niso zadostno odzvali na zdravljenje s hidroklorotiazidom 25 mg, je dodatek zdravila Enviage 300 mg povzročil dodatno znižanje krvnega tlaka, ki je bilo primerljivo z dodatkom irbesartana 300 mg ali amlodipina 10 mg.
English: Enviage has no known clinically relevant interactions with medicinal products commonly used to treat hypertension or diabetes.
Slovenian: Za zdravilo Enviage ni znano nobeno klinično pomembno medsebojno delovanje z drugimi zdravili, ki se pogosto uporabljajo za zdravljenje hipertenzije ali sladkorne bolezni.
English: In patients who did not adequately respond to 5 mg of the calcium channel blocker amlodipine, the addition of Enviage 150 mg had a blood-pressure-lowering effect similar to that obtained by increasing amlodipine dose to 10 mg, but had a lower incidence of oedema (aliskiren 150 mg/amlodipine 5 mg 2.1% vs. amlodipine 10 mg 11.2%).
Slovenian: Pri bolnikih, ki se niso zadostno odzvali na zdravljenje z zaviralcem kalcijevih kanalčkov amlodipinom v odmerku 5 mg, je dodatek zdravila Enviage v odmerku 150 mg povzročil učinek zniževanja krvnega tlaka, ki je bil podoben, kot če bi zvišali odmerek amlodipina na 10 mg, vendar je bila incidenca edemov pri tem nižja (aliskiren 150 mg/amlodipin 5 mg: 2,1 %; v primerjavi z amlodipinom 10 mg: 11,2 %).
English: In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Enviage.
Slovenian: V kontroliranih kliničnih študijah je bila uporaba zdravila Enviage občasno povezana s klinično pomembnimi spremembami standardnih laboratorijskih parametrov.
English: INFORMATION IN BRAILLE Enviage 150 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Enviage 150 mg
English: If you have accidentally taken too many Enviage tablets, consult a doctor immediately.
Slovenian: Če ste vzeli večji odmerek zdravila Enviage, kot bi smeli Če ste pomotoma vzeli več tablet zdravila Enviage, kot bi smeli, se takoj posvetujte z zdravnikom.
English: Its use is therefore not recommended in women who are breast-feeding.
Slovenian: Iz tega razloga uporaba zdravila Enviage ni priporočena za matere, ki dojijo.
English: Inducers of P-gp (St. John's wort, rifampicin) might therefore decrease the bioavailability of Enviage.
Slovenian: Zato bi lahko induktorji P-gp (šentjanževka, rifampicin) zmanjšali biološko uporabnost zdravila Enviage.
English: Serum potassium: Increases in serum potassium were minor and infrequent in patients with essential hypertension treated with Enviage alone (0.9% compared to 0.6% with placebo).
Slovenian: Kalij v serumu: Pri bolnikih z esencialno hipertenzijo, zdravljenih samo z zdravilom Enviage, je redko in v majhni meri prišlo do zvišanja vrednosti kalija v serumu (0,9 % v primerjavi z 0,6 % pri placebu).
English: Enviage is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Slovenian: Zdravilo Enviage je na voljo v pakiranjih, ki vsebujejo po 7, 14, 28, 30, 50, 56, 84, 90, 98 ali 280 tablet.
English: No adjustment of the initial dosage of Enviage is required in patients with mild to severe renal impairment, however caution should be exercised in patients with severe renal impairment.
Slovenian: Pri bolnikih z blago do hudo okvaro ledvic ni treba prilagajati začetnega odmerjanja zdravila Enviage, vendar je pri bolnikih s hudo okvaro ledvic potrebna previdnost.
English: Angioedema has occurred during treatment with Enviage.
Slovenian: Pri zdravljenju z zdravilom Enviage je prišlo do angioedema.
English: Enviage may be used alone or in combination with other antihypertensive agents (see sections 4.4 and
Slovenian: Enviage se lahko jemlje samostojno ali v kombinaciji z drugimi učinkovinami za zniževanje krvnega tlaka (glejte poglavji 4.4 in 5.1).
English: This condition should be corrected prior to administration of Enviage, or the treatment should start under close medical supervision.
Slovenian: Pomanjkanje natrija in/ali hipovolemijo je treba odpraviti pred aplikacijo zdravila Enviage ali pa je treba zdravljenje uvajati pod strogim zdravniškim nadzorom.
English: Coadministration of Enviage had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Slovenian: Sočasna uporaba zdravila Enviage ni pomembno vplivala na farmakokinetične lastnosti atorvastatina, valsartana, metformina in amlodipina.
English: In diabetic hypertensive patients, Enviage provided additive blood pressure reductions when added to ramipril, while the combination of Enviage and ramipril had a lower incidence of cough (1.8%) than ramipril (4.7%).
Slovenian: Pri sladkornih bolnikih s hipertenzijo je dodatek zdravila Enviage k zdravljenju z ramiprilom povzročil dodatno znižanje krvnega tlaka, incidenca kašlja pa je bila ob kombinaciji zdravila Enviage in ramiprila nižja (1,8 %) kot pri zdravljenju samo z ramiprilom (4,7 %).
English: Treatment with Enviage resulted in an overall incidence of adverse reactions similar to placebo up to 300 mg.
Slovenian: Pri zdravljenju z zdravilom Enviage je bila pri odmerkih do 300 mg incidenca vseh neželenih učinkov skupaj podobna kot pri placebu.
English: As a result no dose adjustment for Enviage or these co-administered medicinal products is necessary.
Slovenian: Iz tega razloga pri sočasni uporabi ni treba prilagajati odmerkov zdravila Enviage oziroma navedenih zdravil.
English: Combination therapy studies are available for Enviage added to the diuretic hydrochlorothiazide, the ACEI ramipril, the calcium channel blocker amlodipine, the angiotensin receptor antagonist valsartan, and the beta blocker atenolol.
Slovenian: Izvajali so študije kombiniranega zdravljenja z dodajanjem zdravila Enviage diuretiku hidroklorotiazidu, zaviralcu angiotenzinske konvertaze ramiprilu, zaviralcu kalcijevih kanalčkov amlodipinu, antagonistu angiotenzina II valsartanu in zaviralcu andrenergičnih receptorjev beta atenololu.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/406/007
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/406/007
English: B-type natriuretic peptide (BNP) levels were reduced by 25% in the Enviage arm compared to placebo.
Slovenian: Koncentracije možganskega natriuretičnega peptida (BNP - B-type natriuretic peptide) so bile v skupini z zdravilom Enviage nižje za 25 % v primerjavi s skupino s placebom, vendar klinični pomen tega znižanja ni znan.
English: You should not take Enviage together with grapefruit juice.
Slovenian: Zdravila Enviage se ne sme jemati skupaj z grenivkinim sokom.
English: Digoxin bioavailability may be slightly decreased by Enviage.
Slovenian: Zdravilo Enviage lahko nekoliko zmanjša biološko uporabnost digoksina.
English: Compared to a diuretic (hydrochlorothiazideHCTZ), Enviage 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
Slovenian: V primerjavi z diuretikom hidroklorotiazidom je Enviage po 12 tednih zdravljenja v odmerku 300 mg znižal sistolični/diastolični krvni tlak za 17,0/12,3 mmHg,
English: Enviage has negligible influence on the ability to drive and use machines.
Slovenian: Vpliv zdravila Enviage na sposobnost vožnje in upravljanja s stroji je zanemarljiv.
English: Enviage monotherapy studies have shown blood pressure lowering effects comparable to other classes of antihypertensive agents including ACEI and ARB.
Slovenian: Rezultati študij zdravila Enviage v monoterapiji so pokazali učinke zniževanja krvnega tlaka, ki so primerljivi z učinki drugih skupin antihipertenzivnih zdravil, vključno z zaviralci angiotenzinske konvertaze in antagonisti angiotenzina II.
English: Excessive hypotension was uncommonly (0.1%) seen in patients with uncomplicated hypertension treated with Enviage alone.
Slovenian: Pri bolnikih s hipertenzijo brez zapletov, ki so se zdravili samo z zdravilom Enviage, so občasno (pri 0,1 %) opažali pretirano hipotenzijo.
English: Enviage 300 mg film-coated tablets Aliskiren
Slovenian: Enviage 300 mg filmsko obložene tablete aliskiren
English: Enviage 150 mg film-coated tablets Aliskiren
Slovenian: Enviage 150 mg filmsko obložene tablete aliskiren
English: In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Enviage 300 mg achieved a 20% reduction versus placebo in urinary albumin:creatinine ratio (UACR), i.e. from 58 mg/mmol to 46 mg/mmol.
Slovenian: Dodajanje zdravila Enviage v odmerku 300 mg je v primerjavi s placebom povzročilo 20-odstotno zmanjšanje razmerja med koncentracijo albumina in kreatinina v urinu (UACR - urinary albumin:creatinine ratio), to je od 58 mg/mmol na 46 mg/mmol.
English: NAME OF THE MEDICINAL PRODUCT Enviage 150 mg film-coated tablets
Slovenian: IME ZDRAVILA Enviage 150 mg filmsko obložene tablete
English: No controlled clinical data are available on the use of Enviage in patients with unilateral or bilateral renal artery stenosis, or stenosis to a solitary kidney.
Slovenian: Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oziroma bolnikih s stenozo ledvične arterije v primeru solitarne ledvice o uporabi zdravila Enviage ni na voljo podatkov iz kontroliranih kliničnih študij.
English: NAME OF THE MEDICINAL PRODUCT Enviage 300 mg film-coated tablets
Slovenian: IME ZDRAVILA Enviage 300 mg filmsko obložene tablete
English: When administered with atorvastatin, steady-state Enviage AUC and Cmax increased by 50%.
Slovenian: Zaradi sočasne uporabe z atorvastatinom sta se AUC in Cmax zdravila Enviage v stanju dinamičnega ravnovesja zvišala za 50 %.
English: Caution should be exercised in hypertensive patients with severe renal impairment due to the lack of safety information for Enviage.
Slovenian: Zaradi pomanjkanja podatkov o varnosti zdravila Enviage pri hipertenzivnih bolnikih s hudo okvaro ledvic, je pri teh bolnikih potrebna previdnost.
English: - if you are taking ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumathoid arthritis or atopic dermatitis) or verapamil (a medicine used to lower blood pressure, to correct hearth rhythm or to treat angina pectoris) or quinidine (a medicine used to correct heart rhythm).
Slovenian: Ne jemljite zdravila Enviage - če ste alergični (preobčutljivi) na aliskiren ali katerokoli sestavino zdravila Enviage; če mislite, da bi lahko bili alergični, se posvetujte z zdravnikom; - če ste v času jemanja aliskirena že imeli kdaj angioedem (težave z dihanjem ali s požiranjem ali otekanje obraza, rok, stopal, oči, ustnic in/ali jezika); - v zadnjih 6 mesecih nosečnosti ali če dojite, glejte poglavje Nosečnost in dojenje; - če jemljete ciklosporin (zdravilo, ki se ga uporablja pri presaditvah za preprečevanje zavrnitve organa ali pri drugih boleznih, na primer pri revmatoidnem artritisu ali atopijskem dermatitisu), če jemljete verapamil (zdravilo za zniževanje krvnega tlaka, uravnavanje srčnega ritma ali za zdravljenje angine pektoris) ali če jemljete kinidin (zdravilo za uravnavanje srčnega ritma).
English: What Enviage looks like and contents of the pack Enviage 150 mg film coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side and “NVR” on the other side.
Slovenian: Enviage 150 mg filmsko obložene tablete so bikonveksne okrogle tablete svetlo roza barve, z oznako ‘IL' na eni strani in ‘NVR' na drugi.
English: What Enviage looks like and contents of the pack Enviage 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one side and “NVR” on the other side.
Slovenian: Enviage 300 mg filmsko obložene tablete so bikonveksne ovalne tablete svetlo rdeče barve, z oznako ‘IU' na eni strani in ‘NVR' na drugi.
English: Enviage induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Slovenian: Če so zdravilo Enviage dodali hidroklorotiazidu in ramiprilu, je povzročilo aditiven učinek zniževanja krvnega tlaka.
English: Take special care with Enviage - if you are taking a diuretic (a type of medicine also known as “water” tablets which increases the amount of urine you produce).
Slovenian: Bodite posebno pozorni pri uporabi zdravila Enviage - kadar jemljete diuretike (vrsta zdravil za odvajanje vode, ki povečuje količino urina, ki nastaja v telesu); - če imate moteno delovanje ledvic; - če pride do angioedema (težav z dihanjem ali s požiranjem ali do otekanja obraza, rok, stopal,
English: Sodium and/or volume depleted patients
Slovenian: Bolniki s pomanjkanjem natrija in/ali hipovolemijo
English: What Enviage contains - The active substance is aliskiren (as hemifumarate) 150 mg. - The other ingredients are crospovidone, hypromellose, magnesium stearate, macrogol,
Slovenian: Kaj vsebuje zdravilo Enviage - Zdravilna učinkovina je aliskiren (v obliki hemifumarata) 150 mg. - Pomožne snovi so: krospovidon, hipromeloza, magnezijev stearat, makrogol, mikrokristalna celuloza, povidon, brezvodni koloidni silicijev dioksid, smukec, titanov dioksid (E 171), črni železov oksid (E 172), rdeči železov oksid (E 172).
English: microcrystalline cellulose, povidone, colloidal anhydrous silica, talc, titanium dioxide (E 171),
Slovenian: Kaj vsebuje zdravilo Enviage - Zdravilna učinkovina je aliskiren (v obliki hemifumarata) 300 mg. - Pomožne snovi so: krospovidon, hipromeloza, magnezijev stearat, makrogol, mikrokristalna celuloza, povidon, brezvodni koloidni silicijev dioksid, smukec, titanov dioksid (E 171), črni železov oksid (E 172), rdeči železov oksid (E 172).
English: In hypertensive patients, once-daily administration of Enviage at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
Slovenian: Znižanje krvnega tlaka je bilo odvisno od velikosti odmerka in se je ohranilo skozi celoten 24-urni interval odmerjanja (ohranjena koristnost učinka v zgodnjih jutranjih urah).
English: The average duration of response to treatment was 17.5 months.
Slovenian: Povprečno trajanje odziva na zdravljenje je bilo 17,5 meseca.
English: Further information on Imbruvica can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/imbruvica .
Slovenian: Nadaljnje informacije za zdravilo Imbruvica so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/imbruvica.
English: What measures are being taken to ensure the safe and effective use of Imbruvica?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Imbruvica?
English: The European Medicines Agency decided that Imbruvica's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Imbruvica večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Imbruvica is available as capsules (140 mg) and tablets (140, 280, 420 and 560 mg).
Slovenian: Zdravilo Imbruvica je na voljo v obliki kapsul (140 mg) in tablet (140 mg, 280 mg, 420 mg in 560 mg).
English: Other information about Imbruvica
Slovenian: Druge informacije o zdravilu Imbruvica
English: Imbruvica received a marketing authorisation valid throughout the EU on 21 October 2014.
Slovenian: Za zdravilo Imbruvica je bilo 21. oktobra 2014 izdano dovoljenje za promet, veljavno po vsej EU.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imbruvica have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Imbruvica upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: As for all medicines, data on the use of Imbruvica are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Imbruvica stalno spremljajo.
English: What benefits of Imbruvica have been shown in studies?
Slovenian: Kakšne koristi zdravila Imbruvica so se pokazale v študijah?
English: An overview of Imbruvica and why it is authorised in the EU
Slovenian: Pregled zdravila Imbruvica in zakaj je odobreno v EU
English: What are the risks associated with Imbruvica?
Slovenian: Kakšna tveganja so povezana z zdravilom Imbruvica?
English: Side effects reported with Imbruvica are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Imbruvica, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Why is Imbruvica authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Imbruvica odobreno v EU?
English: These diseases are rare, and Imbruvica was designated an ‘orphan medicine' (a medicine used in rare diseases) for chronic lymphocytic leukaemia on 26 April 2012, mantle cell lymphoma on 12 March 2013 and Waldenström's macroglobulinaemia on 29 April 2014.
Slovenian: Te bolezni so redke, zato je bilo zdravilo Imbruvica določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni), in sicer za kronično limfocitno levkemijo 26. aprila 2012, za limfom plaščnih celic 12. marca 2013 in za Waldenströmovo makroglobulinemijo 29. aprila 2014.
English: Imbruvica can only be obtained with a prescription, and treatment should be started and supervised by a doctor experienced in using cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Imbruvica je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
English: If the patient is taking other medicines that may interact with Imbruvica, or gets severe side effects, the dose may be lowered or treatment interrupted.
Slovenian: Če bolnik jemlje določena druga zdravila, ki lahko vplivajo na delovanje zdravila Imbruvica ali če se pri njem pojavijo resni neželeni učinki, se odmerek lahko po potrebi zmanjša ali zdravljenje prekine.
English: Treatment with Imbruvica should continue for as long as the disease improves or remains stable and the side effects are tolerable.
Slovenian: Zdravljenje z zdravilom Imbruvica se lahko nadaljuje, dokler se bolezen izboljšuje oziroma ostaja stabilna, neželeni učinki pa so znosni.
English: It does this by blocking an enzyme called Bruton's tyrosine kinase (Btk), which promotes survival of B lymphocytes and their migration to the organs where these cells normally divide.
Slovenian: To doseže z zaviranjem encima, imenovanega Brutonova tirozinska kinaza (Btk), ki spodbuja preživetje limfocitov B in njihovo preselitev v organe, v katerih se te celice običajno delijo.
English: For more information about using Imbruvica, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Imbruvica glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Imbruvica and what is it used for?
Slovenian: Kaj je zdravilo Imbruvica in za kaj se uporablja?
English: The most common side effects with Imbruvica (which may affect more than 1 in 5 people) are diarrhoea, neutropenia (low levels of neutrophils, a type of white blood cell), pain in muscles and bones, haemorrhage (bleeding), bruising, rash, feeling sick and thrombocytopenia (low blood platelet counts).
Slovenian: Najpogostejši neželeni učinki zdravila Imbruvica (ki se lahko pojavijo pri več kot 1 od 5 bolnikov) so driska, nevtropenija (nizke ravni nevtrofilcev, vrste belih krvnih celic) mišično-skeletne bolečine (bolečine v mišicah in kosteh), krvavitve, podplutbe, izpuščaj, navzeja (siljenje na bruhanje) in trombocitopenija (nizko število trombocitov).
English: Chronic lymphocytic leukaemia
Slovenian: Kronična limfocitna levkemija
English: The most serious side effects are neutropenia, pneumonia (lung infection) and thrombocytopenia.
Slovenian: Najresnejši neželeni učinki so nevtropenija, pljučnica (okužba pljuč) in trombocitopenija.
English: Imbruvica is a medicine for treating adult patients with the following blood cancers:
Slovenian: Zdravilo Imbruvica se uporablja za zdravljenje odraslih bolnikov z naslednjimi vrstami krvnega raka:
English: • mantle cell lymphoma in patients whose disease does not respond to or has come back after previous treatment;
Slovenian: • limfomom plaščnih celic pri bolnikih, pri katerih se bolezen ne odziva ali se je ponovila po predhodnem zdravljenju;
English: The average time before patients died or the disease got worse was 15 months with Imbruvica versus 6 months with temsirolimus.
Slovenian: Povprečen čas do smrti bolnikov ali poslabšanja bolezni je bil 15 mesecev pri jemanju zdravila Imbruvica v primerjali s šestimi meseci pri jemanju temsirolimusa.
English: A second study in 280 such patients compared Imbruvica with another cancer medicine, temsirolimus.
Slovenian: V drugi študiji pri 280 bolnikih so zdravilo Imbruvica primerjali z drugim zdravilom za zdravljenje raka, temsirolimusom.
English: For patients with mantle cell lymphoma the dose is 560 mg once a day, for patients with chronic lymphocytic leukaemia or Waldenström's macroglobulinaemia the usual dose of Imbruvica is 420 mg once a day.
Slovenian: Za bolnike z limfomom plaščnih celic je odmerek 560 mg enkrat na dan, za bolnike s kronično limfocitno levkemijo ali Waldenströmovo makroglobulinemijo pa 420 mg enkrat na dan.
English: The active substance in Imbruvica, ibrutinib, works against cancerous B lymphocytes, a type of white blood cells.
Slovenian: Učinkovina v zdravilu Imbruvica, ibrutinib, deluje proti rakavim limfocitom B, tj. vrsti belih krvnih celic.
English: The company that markets Imbruvica needs to provide further data on the benefits of Imbruvica in the treatment of chronic lymphocytic leukaemia from follow-up of previously treated patients.
Slovenian: Podjetje, ki trži zdravilo Imbruvica, mora posredovati dodatne podatke o koristih zdravila Imbruvica pri zdravljenju kronične limfocitne levkemije na podlagi spremljanja predhodno zdravljenih bolnikov iz prve študije.
English: Response to treatment was measured as a reduction in the blood levels of the protein IgM, which is present in high levels in patients with Waldenström's disease.
Slovenian: Merilo odziva na zdravljenje je bilo znižanje v krvi ravni beljakovine IgM, ki je v visoki koncentraciji prisotna pri bolnikih z Waldenströmovo makroglobulinemijo.
English: By blocking Btk, ibrutinib decreases survival and migration of B lymphocytes, thereby delaying progression of the cancer.
Slovenian: Ibrutinib z zaviranjem encima Btk zmanjša stopnjo preživetja in preselitve limfocitov B, s čimer zadržuje napredovanje raka.
English: St. John's wort (a herbal remedy used for depression and anxiety) must not be used in patients treated with Imbruvica.
Slovenian: Šentjanževka (zeliščni pripravek, ki se uporablja proti depresiji in tesnobi) se ne sme uporabljati pri bolnikih, ki se zdravijo z zdravilom Imbruvica.
English: • chronic lymphocytic leukaemia (CLL) in both previously treated and untreated patients;
Slovenian: • kronično limfocitno levkemijo (KLL) pri predhodno zdravljenih in predhodno nezdravljenih bolnikih;
English: In addition, Imbruvica was effective in patients with mantle cell lymphoma that did not respond to or had come back after previous treatment, a group of patients with poor prognosis and few other treatment options.
Slovenian: Učinkovito je bilo tudi pri bolnikih z limfomom plaščnih celic, ki se ni odzval na predhodno zdravljenje ali se je po njem ponovil, tj. v skupini s slabo prognozo in malo drugimi možnostmi zdravljenja.
English: Waldenström's macroglobulinaemia
Slovenian: Waldenströmova makroglobulinemija